Immunoglobulin A nephropathy (IgAN)
Efficacy and safety of iptacopan in patients with primary IgA nephropathy: results from an interim analysis of the Phase 3 APPLAUSE-IgAN study
Dana V. Rizk
Real world analysis of patients with immunoglobulin A nephropathy – diagnosis and disease monitoring
Richard Lafayette
Treatment patterns in patients with immunoglobulin a nephropathy – evidence from real-world data
Richard Lafayette
Treatment goals from the perspective of immunoglobulin a nephropathy patients - results from a real-world study
Richard Lafayette
Baseline characteristics of the ALIGN trial: a Phase 3 randomized, double-blind, placebo-controlled clinical trial of atrasentan in patients with IgAN
Hiddo J. L Heerspink
ASSIST: a randomized, double-blind, placebo-controlled crossover trial of atrasentan in patients with IgA nephropathy (IgAN) on SGLT2i
Irene L. Noronha
BEYOND: a Phase 3, randomized, double-blind, placebo-controlled trial of zigakibart in adults with IgA nephropathy
Hernan Trimarchi
Complement 3 glomerulopathy (C3G)
Self-reported quality of life in complement 3 glomerulopathy patients delineated by CKD stage: a real-world, multi-country survey
Raisa Sidhu
Prevalence and clinical characteristics of kidney transplants in complement 3 glomerulopathy patients: results from a real-world, multi-country survey
Raisa Sidhu
Characteristics of patients with complement 3 glomerulopathy (C3G) in a US multi-center assessment
Briana Ndife
CKD progression in patients with complement 3 glomerulopathy (C3G) in a US multi-center assessment
Briana Ndife
Immune-complex-mediated glomerulonephritis (IC-MPGN)
Safety and efficacy of iptacopan in adolescent patients with idiopathic (primary) immune-complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
Nicholas Webb
Others
Identifying opportunities to improve evaluation for hematuria in a large health system
Alexander R. Chang
Single dose of iptacopan treatment rapidly decreases plasma complement Bb levels
Robert Schmouder
Assessment of the effect of hepatic impairment on iptacopan pharmacokinetics
Kenneth Kulmatycki